Breast Reconstruction Market Analysis | United States | 2017-2023 | MedCore

Breast Reconstruction Market Analysis | United States | 2017-2023 | MedCore

0

Breast reconstruction following mastectomy for treatment of cancer is becoming increasingly popular in the United States. Breast reconstruction is a plastic surgery procedure in which the shape of the breast is rebuilt. The number of these reconstructive procedures represents less than 30% of plastic surgery breast augmentation procedures. Breast reconstruction is typically performed after mastectomy, although not all mastectomy patients elect to have reconstructive surgery. Elderly patients are not only less likely to opt for breast reconstruction surgery, but are less likely to proceed with a mastectomy following breast cancer diagnosis. The incidence of breast cancer has been increasing in women under the age of 40, and this population is much more likely not only to proceed with mastectomy, but to follow up with a breast reconstruction procedure. Over 130,000 mastectomies were performed in the U.S. in 2016, and of these, over 70% of patients elected for breast reconstruction surgery. This percentage was significantly higher in the U.S. compared with other countries. Therefore, in the United States, the number of breast reconstruction procedures is highly correlated with the number of mastectomies performed. The Women’s Health and Cancer Rights Act (WHCRA), established in 1998, ensures full reimbursement for most procedures done on women with breast cancer who elect to have their breasts rebuilt following mastectomy. The procedure is extremely involved and is done in an inpatient setting. Breast reconstructions have started to be conducted immediately after the mastectomy procedure to reduce recovery time.

  • Year: 2017
  • Scope: 2013-2023
  • Region: United States
  • Published Date: 7/1/2017
  • Pages: 530
  • Type: MedCore

Despite a decline in the rate of bilateral reconstructions, the total breast reconstruction market is still expected to grow in upcoming years, fueled by the continuing success of allograft products, especially Acelity’s AlloDerm®, which has always been the dominant product in this space. The outstanding clinical reviews and patient satisfaction garnered by allograft devices will allow them to continue to be the device of choice when it comes to breast reconstruction.

Recently there has been a trend in the U.S. for patients to opt for contralateral prophylactic mastectomy (CPM), where breast cancer is only diagnosed in one breast but the decision to remove the second breast is made for preventative measures. The decision to undergo CPM is based primarily on two important factors. Firstly the decision is often made based on an assessment of risk factors including family history of breast cancer incidence and the presence of BRCA1 or BRCA2 gene mutations, which studies have shown to be linked to the development of breast cancer. Secondly, many patients elect to go through with CPM for aesthetic reasons.

Segments Covered in This Market

  • Allograft Market
  • Xenograft Market
  • Alloplast Market

Report Data Types Included

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • 10 Year Scope (3 Year Historical + 7 Year Forecast Period)
  • Market Drivers & Limiters for Each Segment
  • Competitive Analysis with Market Shares
  • Product Portfolios
  • Related Press Releases from Top Competitors

Companies Analyzed

Acelity’s domination in the allograft market was due solely to its AlloDerm® allograft product for breast reconstruction, an acellular dermal matrix (ADM). Ethicon was present in the allograft segment with its pre-hydrated ADM product, FlexHD®, which is available through a strategic alliance between Ethicon and the Musculoskeletal Transplant Foundation (MTF). C. R. Bard offers an ADM device, AlloMax™. AlloMax™ undergoes a process of tissue-graft cleaning and preservation known as the Tutoplast® process by RTI Biologics beginning with a comprehensive donor screening, followed by standard serological screens. Other companies analyzed include Covidien and Integra LifeSciences.

About Our In-Depth MedCore Research

Our analysts meticulously research for up to 3 to 4 months to put together one suite of reports (MedSuite), which is a comprehensive analysis on a group of healthcare markets. A MedCore is one portion of that analysis that focuses on one market segment, and provides further detailed segmentation to get a much more granular set of market data.

This MedCore is also found in the full report suite titled U.S. Market Report Suite for Soft Tissue Reinforcement and Regeneration – MedSuite

Learn More about these product types



The "US Market Report Suite for Soft Tissue Reinforcement and Regeneration 2017 - MedSuite" includes analysis on the following companies currently active in this market:
LifeCell
Organogenesis
C.R. Bard
Ethicon
Covidien
Arthrex
ASTORA
Wright Medical
Integra LifeSciences
Smith & Nephew
MiMedx
Boston Scientific
Systagenix
BioHorizons
Atrium Medical
Coloplast
Stryker
Cook Medical
Johnson & Johnson
Osiris
Soluble Systems
Synovis/Baxter
KCI
RTI Biologics
Geistlich
TEI
Zimmer Biomet
ACell
Aesculap/B. Braun
Gore Medical
Medtronic
Dentsply
Others include: Medline, MTF, WL Gore, Tutogen, Novus Scientific, Ariste Medical
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.




iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology


close-link
close-link

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers

close-link
close-link
close-link